dose escalation pan-fgfr (fibroblast growth factor receptor) inhibitor (rogaratinib)

Conditions: Neoplasms

Summary: * this was the first study where bay1163877 was given to humans. impact of the study was to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan fgfr inhibitor. patients (all comers) received the study drug treatment in a dose-escalation scheme (no placebo group) to determine the safety, tolerability and maximum tolerated dose (mtd) of bay1163877. the relative bioavailability of liquid service formulation and tablets was determined. * after the mtd was defined patients with solid tumors (all comers), lung cancer (lung adenocarcinoma \& squamous non-small cell lung cancer), head and neck cancer or bladder cancer was enrolled according to their fgfr expression profile (biomarker stratification). * the study also assessed the pharmacokinetics, biomarker status, pharmacodynamic parameters and tumor response of bay1163877. * bay1163877 was given twice daily as oral application. treatment was stopped if the tumor continued to grow, if side effects, which the patient cannot tolerate, occurred or if the patient decided to exit treatment.


Eligibility criteria:
inclusion criteria: * for dose escalation: participants with any type of solid tumor (all comer) were eligible for dose escalation and dose expansion at mtd in part 1; participants enrolled for dose expansion (mtd expansion cohort "all comer") were stratified according to high fibroblast growth factor receptor (fgfr) expression levels / fgfr mutation using archival or fresh tumor biopsy material * for expansion cohorts: participants were eligible for part 2 only if they have histological or cytological confirmed squamous non-small cell lung cancer (sqnsclc), lung adenocarcinoma, head and neck cancer or bladder cancer (bc). all participants in part 2 were stratified according to high fgfr expression levels fgfr mutation using archival or fresh tumor biopsy specimen. bc participants with low overall fgfr expression levels could be included if activating fgfr3 (fgfr tyrosine kinases 3) mutations were confirmed * participants must have measurable disease (response evaluation criteria in solid tumors (recist 1.1)) * eastern cooperative oncology group (ecog) performance status 0 - 2 * bone marrow, liver and renal functions as assessed by adequate laboratory methods to be conducted within 7 days prior to starting study treatment * glomerular filtration rate (gfr) ≥ 30 ml/min/1.73 m\^2 according to the modified diet in renal disease (mdrd) abbreviated formula exclusion criteria: * previous treatment with anti-fgfr directed therapies (e.g. receptor tyrosine kinase inhibitors or fgfr-specific antibodies) * concomitant therapies that cannot be discontinued or switched to a different medication prior to study entry that are known to increase serum phosphate levels are not permitted within 4 weeks prior to start of study treatment) * anticancer chemotherapy or immunotherapy during the study or within 5-halflives prior to start of study treatment. mitomycin c, nitrosoureas or monoclonal antibodies with anticancer activity (e.g. bevacizumab or cetuximab etc.) should not be given within 6 weeks before starting to receive study treatment or within 6 weeks of pre-treatment biopsy for biomarker (p-erk1/2) studies

Keywords: phase i dose escalation refractory, locally advanced or metastatic solid tumor bladder cancer squamous non-small cell lung cancer pan-fgfr inhibitor lung adenocarcinoma head and neck cancer